116 related articles for article (PubMed ID: 6440150)
1. Influence of verapamil and diltiazem on aggregatory responses in cat and rabbit platelet rich plasma.
Lippton HL; Horwitz PM; McNamara DB; Landry AZ; Kadowitz PJ
Prostaglandins Leukot Med; 1984 Oct; 16(1):121-30. PubMed ID: 6440150
[TBL] [Abstract][Full Text] [Related]
2. Anti-aggregatory actions of calcium channel blockers in cat platelets.
Schmunk GA; Lefer AM
Res Commun Chem Pathol Pharmacol; 1982 Feb; 35(2):179-87. PubMed ID: 6803310
[TBL] [Abstract][Full Text] [Related]
3. The effects of amrinone on human platelet aggregation: evidence that amrinone does not act through a cyclic nucleotide mechanism in platelet rich plasma.
Lippton HL; Horwitz PM; McNamara DB; Ignarro LJ; Landry AZ; Hyman AL; Kadowitz PJ
Prostaglandins Leukot Med; 1985 May; 18(2):193-204. PubMed ID: 3925461
[TBL] [Abstract][Full Text] [Related]
4. Adenosine potentiates the inhibitory effects of calcium channel antagonists on human platelet aggregation induced by thromboxane A2 or U46619.
Johnson GJ; Leis LA; Francis GS
Thromb Res; 1990 Jul; 59(1):139-48. PubMed ID: 2399526
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet aggregation by diltiazem. Comparison with verapamil and nifedipine and inhibitory potencies of diltiazem metabolites.
Kiyomoto A; Sasaki Y; Odawara A; Morita T
Circ Res; 1983 Feb; 52(2 Pt 2):I115-9. PubMed ID: 6831645
[TBL] [Abstract][Full Text] [Related]
6. Effects of diltiazem and verapamil on ADP-induced rabbit platelet shape change and aggregation.
Dehpour AR; Samadian T; Akhavan MM; Meysamee F; Delfan A
Gen Pharmacol; 1995 Oct; 26(6):1295-9. PubMed ID: 7590122
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of thromboxane A2/prostaglandin H2 by 13-azaprostanoic acid prevents platelet deposition to the de-endothelialized rabbit aorta in vivo.
Le Breton GC; Lipowski JP; Feinberg H; Venton DL; Ho T; Wu KK
J Pharmacol Exp Ther; 1984 Apr; 229(1):80-4. PubMed ID: 6423815
[TBL] [Abstract][Full Text] [Related]
8. Disparate effects of the calcium-channel blockers, nifedipine and verapamil, on alpha 2-adrenergic receptors and thromboxane A2-induced aggregation of human platelets.
Johnson GJ; Leis LA; Francis GS
Circulation; 1986 Apr; 73(4):847-54. PubMed ID: 3004784
[TBL] [Abstract][Full Text] [Related]
9. [Effect of a new thromboxane A2 antagonist, S-145, on platelet aggregation].
Kakushi H; Shike T; Uchida K
Nihon Yakurigaku Zasshi; 1989 Mar; 93(3):171-8. PubMed ID: 2731807
[TBL] [Abstract][Full Text] [Related]
10. Influence of nifedipine, verapamil and diltiazem on pulmonary vascular resistance and vasoconstrictors in cats.
Erdemli O; Hao Q; Cai B; Lippton HL; Hyman A
Arch Int Pharmacodyn Ther; 1994; 328(2):165-79. PubMed ID: 7535994
[TBL] [Abstract][Full Text] [Related]
11. Characterization of thromboxane A2/prostaglandin H2 (TXA2/PGH2) receptors of rat platelets and their interaction with TXA2/PGH2 receptor antagonists.
Hanasaki K; Arita H
Biochem Pharmacol; 1988 Oct; 37(20):3923-9. PubMed ID: 2973322
[TBL] [Abstract][Full Text] [Related]
12. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1984 Jan; 228(1):240-4. PubMed ID: 6319669
[TBL] [Abstract][Full Text] [Related]
13. Effects of methylprednisolone and hydrocortisone on aggregation of rabbit platelets induced by arachidonic acid and other aggregating substances.
Glass F; Lippton H; Kadowitz PJ
Thromb Haemost; 1981 Dec; 46(4):676-9. PubMed ID: 6800048
[TBL] [Abstract][Full Text] [Related]
14. Reversal of thromboxane A2/prostaglandin H2 and ADP-induced calcium release in intact platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H8-13. PubMed ID: 2409821
[TBL] [Abstract][Full Text] [Related]
15. Effects of prostaglandins, cAMP, and changes in cytosolic calcium on platelet aggregation induced by a thromboxane A2 mimic (U46619).
Yun JC; Ohman KP; Gill JR; Keiser H
Can J Physiol Pharmacol; 1991 May; 69(5):599-604. PubMed ID: 1650650
[TBL] [Abstract][Full Text] [Related]
16. Thromboxane A2/prostaglandin H2 directly stimulates platelet shape change independent of secreted ADP.
Parise LV; Venton DL; Le Breton GC
J Pharmacol Exp Ther; 1982 Jul; 222(1):276-81. PubMed ID: 7086705
[TBL] [Abstract][Full Text] [Related]
17. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation.
Glusa E; Bevan J; Heptinstall S
Thromb Res; 1989 Jul; 55(2):239-245. PubMed ID: 2528843
[TBL] [Abstract][Full Text] [Related]
18. Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthase inhibitors.
Onoda JM; Sloane BF; Honn KV
Thromb Res; 1984 Jun; 34(5):367-78. PubMed ID: 6377570
[TBL] [Abstract][Full Text] [Related]
19. Effects of verapamil and diltiazem on human platelet function.
Addonizio VP; Fisher CA; Strauss JF; Wachtfogel YT; Colman RW; Josephson ME
Am J Physiol; 1986 Mar; 250(3 Pt 2):H366-71. PubMed ID: 3006516
[TBL] [Abstract][Full Text] [Related]
20. Thromboxane A2/prostaglandin H2 mobilizes calcium in human blood platelets.
Brace LD; Venton DL; Le Breton GC
Am J Physiol; 1985 Jul; 249(1 Pt 2):H1-7. PubMed ID: 3925795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
